Cryotherapy plus imiquimod active in cutaneous melanoma mets

Cryotherapy + imiquimod active in cutaneous melanoma mets

(HealthDay)—Cryotherapy combined with topical imiquimod 5 percent is an active treatment for locoregional cutaneous metastases of melanoma (LCMM), according to research published online Dec. 12 in the Journal of Dermatology.

Noting that treatment of LCMM represents a therapeutic challenge, Nancy Rivas-Tolosa, M.D., from the Instituto Valenciano de Oncología in Valencia, Spain, and colleagues evaluated the efficacy of the combination of and topical imiquimod 5 percent for treating the disease. The authors documented the locoregional cutaneous response to the treatment in 20 patients diagnosed with LCMM.

The researchers found that 65 percent of patients responded to treatment after a mean of five sessions: 40 percent with complete response and 25 percent with partial response. In 80 percent of patients, systemic disease progressed.

"Cryotherapy followed by topical imiquimod 5 percent is simple to apply, has minimal adverse effects, and provides response rates similar to other, more complex options," the authors write.

Explore further

Intralesional IL-2 promising for cutaneous melanoma metastases

More information: Abstract
Full Text (subscription or payment may be required)

Copyright © 2015 HealthDay. All rights reserved.

Citation: Cryotherapy plus imiquimod active in cutaneous melanoma mets (2015, December 21) retrieved 26 February 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments